Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 25 (3)

Adropin as A Fat-Burning Hormone With Multiple Functions-Review of a Decade of Research


Adropin as A Fat-Burning Hormone With Multiple Functions-Review of a Decade of Research

Mariami Jasaszwili et al. Molecules.


Adropin is a unique hormone encoded by the energy homeostasis-associated (Enho) gene. Adropin is produced in the liver and brain, and also in peripheral tissues such as in the heart and gastrointestinal tract. Furthermore, adropin is present in the circulatory system. A decade after its discovery, there is evidence that adropin may contribute to body weight regulation, glucose and lipid homeostasis, and cardiovascular system functions. In this review, we summarize and discuss the physiological, metabolic, and pathophysiological factors regulating Enho as well as adropin. Furthermore, we review the literature addressing the role of adropin in adiposity and type 2 diabetes. Finally, we elaborate on the role of adropin in the context of the cardiovascular system, liver diseases, and cancer.

Keywords: Enho; adiposity; adropin; cancer; cardiovascular system; liver; metabolism; type 2 diabetes.

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.


Figure 1
Figure 1
Summary of the biological effects of adropin.

Similar articles

See all similar articles


    1. Kumar K.G., Trevaskis J.L., Lam D.D., Sutton G.M., Koza R.A., Chouljenko V.N., Kousoulas K.G., Rogers P.M., Kesterson R.A., Thearle M., et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8:468–481. doi: 10.1016/j.cmet.2008.10.011. - DOI - PMC - PubMed
    1. Butler A.A., Zhang J., Price C.A., Stevens J.R., Graham J.L., Stanhope K.L., King S., Krauss R.M., Bremer A.A., Havel P.J. Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates. J. Biol. Chem. 2019;294:9706–9719. doi: 10.1074/jbc.RA119.007528. - DOI - PMC - PubMed
    1. Yolbas S., Kara M., Kalayci M., Yildirim A., Gundogdu B., Aydin S., Koca S.S. ENHO gene expression and serum adropin level in rheumatoid arthritis and systemic lupus erythematosus. Adv. Clin. Exp. Med. 2018;27:1637–1641. doi: 10.17219/acem/75944. - DOI - PubMed
    1. Butler A.A., Tam C.S., Stanhope K.L., Wolfe B.M., Ali M.R., O’Keeffe M., St-Onge M.P., Ravussin E., Havel P.J. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J. Clin. Endocrinol. Metab. 2012;97:3783–3791. doi: 10.1210/jc.2012-2194. - DOI - PMC - PubMed
    1. Stein L.M., Yosten G.L., Samson W.K. Adropin acts in brain to inhibit water drinking: potential interaction with the orphan G protein-coupled receptor, GPR19. Am. J. Physiol. 2016;310:R476–R480. doi: 10.1152/ajpregu.00511.2015. - DOI - PMC - PubMed